Abstract
The introduction of hyperthermic intraperitoneal chemotherapy (HIPEC) was hoped to transform the management of peritoneal metastases, paving the way for pioneering research. Although, a plethora of published studies on the technique exist, conclusive results stemming from randomized data remain elusive. The aim of this study is to assess the cumulative comprehensive available evidence for the use vs non-use of HIPEC treatment in gastrointestinal and biliary tract (GI) malignancies and set the current standpoint of GI HIPEC research both for prevention (adjuvant) and treatment (metastatic) of peritoneal metastases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
